Exscientia
在场
Exscientia 是一家在股票代码 EXAI (GB) 下上市的公司。
高管
查看带有其 24 名主要高管的组织结构图
Exscientia 搜索最多的简介
- David Hallett, Interim Chief Executive Officer and Chief Scientifi...
- Franziska Michor, Director
- Elizabeth Crain, Chairman of the Board
高管在Exscientia变化
- John Overington 曾任 Chief Data Officer, 现升职为 Chief Technology Officer (新闻发布的2024六月7号).
- Marie-Louise Fjaellskog已作为Interim Chief Medical Officer加入公司 (新闻发布的2024六月7号).
- David Hallett 曾任 Chief Scientific Officer, 现升职为 Chief Scientific Officer, Director and Interim Chief Executive Officer (新闻发布的2024二月17号).
创建提醒
跟踪 Exscientia 的高管变动
生物技术
Exscientia 拥有 2,318 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Exscientia 的最新新闻稿
- Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
- Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
- Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
- Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
- Exscientia Business and Financial Update for the Full Year 2023
- Exscientia to Present at Upcoming Investor Conferences in March
- Exscientia plc (Nasdaq: EXAI) today filed the attached disclosure to the U.S. Securities and Exchange Commission (SEC)
- Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
- Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
- View more press releases Close
关于 Exscientia 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 David Hallett 
